AIM: Treatment of vitamin D deficiency is an important aspect of the management of osteoporosis, particularly in the elderly. Most well-described regimens in current use involve daily dosing and thus require long-term compliance to be effective. In New Zealand, no preparation containing only low-dose vitamin D suitable for daily use is available. We describe a high-dose regimen for rapid correction of vitamin D deficiency, which makes use of the calciferol 50 000 international unit (IU) tablets available in this country. METHODS: Thirty two women (mean age 76 +/- 4 years; range 67-84 years) with serum 25-hydroxyvitamin D concentrations = or <10 microg/l were treated with oral calciferol 50 000 IU daily for 10 days. RESULTS: At an average time after treatment of four months, serum 25-hydroxyvitamin D increased from 8 +/- 1 microg/l to 21 +/- 5 microg/l, bringing all but one patient within the reference range (14-76 microg/l). Serum parathyroid hormone level decreased after treatment by 0.7 +/- 1.7 pmol/l (p <0.05), and alkaline phosphatase activity decreased by 5 +/- 11 u/l (p <0.05). Serum calcium increased by 0.06 +/- 0.08 mmol/l (p <0.001), but all values were within the reference range. Data collected from a separate cohort of elderly inpatients showed that similar increases could be achieved with a single 300 000 IU dose, and suggested that serum 25-hydroxyvitamin D levels decline with a half-life of 90 days. CONCLUSIONS: This regimen provides a simple, safe and effective way of managing vitamin D deficiency. Its short-term nature may result in higher compliance than daily dosing regimens.
AIM: Treatment of vitamin D deficiency is an important aspect of the management of osteoporosis, particularly in the elderly. Most well-described regimens in current use involve daily dosing and thus require long-term compliance to be effective. In New Zealand, no preparation containing only low-dose vitamin D suitable for daily use is available. We describe a high-dose regimen for rapid correction of vitamin D deficiency, which makes use of the calciferol 50 000 international unit (IU) tablets available in this country. METHODS: Thirty two women (mean age 76 +/- 4 years; range 67-84 years) with serum 25-hydroxyvitamin D concentrations = or <10 microg/l were treated with oral calciferol 50 000 IU daily for 10 days. RESULTS: At an average time after treatment of four months, serum 25-hydroxyvitamin D increased from 8 +/- 1 microg/l to 21 +/- 5 microg/l, bringing all but one patient within the reference range (14-76 microg/l). Serum parathyroid hormone level decreased after treatment by 0.7 +/- 1.7 pmol/l (p <0.05), and alkaline phosphatase activity decreased by 5 +/- 11 u/l (p <0.05). Serum calcium increased by 0.06 +/- 0.08 mmol/l (p <0.001), but all values were within the reference range. Data collected from a separate cohort of elderly inpatients showed that similar increases could be achieved with a single 300 000 IU dose, and suggested that serum 25-hydroxyvitamin D levels decline with a half-life of 90 days. CONCLUSIONS: This regimen provides a simple, safe and effective way of managing vitamin D deficiency. Its short-term nature may result in higher compliance than daily dosing regimens.
Authors: Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams Journal: J Clin Endocrinol Metab Date: 2012-04-26 Impact factor: 5.958
Authors: J J Cannell; R Vieth; J C Umhau; M F Holick; W B Grant; S Madronich; C F Garland; E Giovannucci Journal: Epidemiol Infect Date: 2006-09-07 Impact factor: 2.451
Authors: Melissa O Premaor; Rosana Scalco; Marília J S da Silva; Pedro E Froehlich; Tania W Furlanetto Journal: J Bone Miner Metab Date: 2008-11-01 Impact factor: 2.626
Authors: Marlous Toren-Wielema; Ruth Veenhuizen; Jan Willem Kappelle; Nic Veeger; Eric van Roon Journal: Drugs Aging Date: 2018-12 Impact factor: 3.923